MariMed Statistics
Total Valuation
MariMed has a market cap or net worth of $64.54 million. The enterprise value is $150.58 million.
| Market Cap | 64.54M |
| Enterprise Value | 150.58M |
Important Dates
The last earnings date was Wednesday, August 2, 2023, after market close.
| Earnings Date | Aug 2, 2023 |
| Ex-Dividend Date | n/a |
Share Statistics
MariMed has 379.64 million shares outstanding. The number of shares has increased by 9.46% in one year.
| Shares Outstanding | 379.64M |
| Shares Change (YoY) | +9.46% |
| Shares Change (QoQ) | -0.21% |
| Owned by Insiders (%) | 13.89% |
| Owned by Institutions (%) | 0.79% |
| Float | 341.33M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 23.31 |
| PS Ratio | 0.42 |
| Forward PS | 0.36 |
| PB Ratio | 0.92 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.99 |
| EV / EBITDA | 9.33 |
| EV / EBIT | 22.18 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.44.
| Current Ratio | 1.55 |
| Quick Ratio | 0.64 |
| Debt / Equity | 1.44 |
| Debt / EBITDA | 6.28 |
| Debt / FCF | n/a |
| Interest Coverage | 0.84 |
Financial Efficiency
Return on equity (ROE) is -23.66%.
| Return on Equity (ROE) | -23.66% |
| Return on Assets (ROA) | -8.29% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | $211,028 |
| Profits Per Employee | -$23,140 |
| Employee Count | 721 |
| Asset Turnover | 0.78 |
| Inventory Turnover | 3.79 |
Taxes
In the past 12 months, MariMed has paid $8.61 million in taxes.
| Income Tax | 8.61M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.18% in the last 52 weeks. The beta is 2.81, so MariMed's price volatility has been higher than the market average.
| Beta (5Y) | 2.81 |
| 52-Week Price Change | -57.18% |
| 50-Day Moving Average | 0.21 |
| 200-Day Moving Average | 0.28 |
| Relative Strength Index (RSI) | 40.51 |
| Average Volume (20 Days) | 406,828 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MariMed had revenue of $152.15 million and -$16.68 million in losses. Loss per share was -$0.04.
| Revenue | 152.15M |
| Gross Profit | 54.12M |
| Operating Income | 11.40M |
| Pretax Income | -8.03M |
| Net Income | -16.68M |
| EBITDA | 16.13M |
| EBIT | 6.79M |
| Loss Per Share | -$0.04 |
Balance Sheet
The company has $15.23 million in cash and $101.27 million in debt, giving a net cash position of -$86.04 million or -$0.23 per share.
| Cash & Cash Equivalents | 15.23M |
| Total Debt | 101.27M |
| Net Cash | -86.04M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | 70.51M |
| Book Value Per Share | 0.19 |
| Working Capital | 19.44M |
Cash Flow
In the last 12 months, operating cash flow was $15.62 million and capital expenditures -$20.74 million, giving a free cash flow of -$5.12 million.
| Operating Cash Flow | 15.62M |
| Capital Expenditures | -20.74M |
| Free Cash Flow | -5.12M |
| FCF Per Share | -$0.01 |
Margins
Gross margin is 35.57%, with operating and profit margins of 7.49% and -10.97%.
| Gross Margin | 35.57% |
| Operating Margin | 7.49% |
| Pretax Margin | -5.28% |
| Profit Margin | -10.97% |
| EBITDA Margin | 10.60% |
| EBIT Margin | 4.46% |
| FCF Margin | -3.36% |
Dividends & Yields
MariMed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.46% |
| Shareholder Yield | -9.46% |
| Earnings Yield | -25.85% |
| FCF Yield | -7.93% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MariMed has an Altman Z-Score of 0.57 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.57 |
| Piotroski F-Score | 2 |